{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:11:55Z","timestamp":1789459915910,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17824893"],"award-info":[{"award-number":["17824893"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20590810"],"award-info":[{"award-number":["20590810"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["21K07943"],"award-info":[{"award-number":["21K07943"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17K09468"],"award-info":[{"award-number":["17K09468"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["24591020"],"award-info":[{"award-number":["24591020"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17877850"],"award-info":[{"award-number":["17877850"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["15K09052"],"award-info":[{"award-number":["15K09052"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["23591017"],"award-info":[{"award-number":["23591017"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["12008507"],"award-info":[{"award-number":["12008507"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013227","name":"Health Promotion Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coi.2025.102564","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T04:38:25Z","timestamp":1747715905000},"page":"102564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["\u2018Can we cure IgG4-related diseases?\u2019"],"prefix":"10.1016","volume":"95","author":[{"given":"Kazuichi","family":"Okazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Ikeura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102564_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-011-0508-6","article-title":"Research Program for Intractable Disease by Ministry of Health, Labor and Welfare (MHLW) Japan G4 team. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details","volume":"22","author":"Umehara","year":"2012","journal-title":"Mod Rheuma"},{"key":"10.1016\/j.coi.2025.102564_bib2","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/art.34593","article-title":"Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations","volume":"64","author":"Stone","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102564_bib3","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/MPA.0000000000000382","article-title":"Autoimmune pancreatitis: the past, present, and future","volume":"44","author":"Okazaki","year":"2015","journal-title":"Pancreas"},{"key":"10.1016\/j.coi.2025.102564_bib4","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2665-9913(19)30006-2","article-title":"IgG4-related disease in the Japanese population: a genome-wide association study","volume":"1","author":"Terao","year":"2019","journal-title":"Lancet Rheuma"},{"key":"10.1016\/j.coi.2025.102564_bib5","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"vander Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102564_bib6","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/gutjnl-2015-310336","article-title":"Pathogenicity of IgG in patients with IgG4-related disease","volume":"65","author":"Shiokawa","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102564_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00535-022-01891-7","article-title":"Current status of type 1 (IgG4-related) autoimmune pancreatitis","volume":"57","author":"Uchida","year":"2022","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102564_bib8","article-title":"The role of IgG4 in autoimmunity and rheumatic diseases","volume":"12","author":"Maslinska","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102564_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jaci.2014.03.034","article-title":"De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease","volume":"134","author":"Mattoo","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102564_bib10","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1136\/annrheumdis-2014-205799","article-title":"B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease","volume":"74","author":"Della-Torre","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102564_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2015.12.1330","article-title":"Clonal expansion of CD4 cytotoxic T lymphocytes in patients with IgG-related disease","volume":"138","author":"Mattoo","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102564_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/all.12342","article-title":"Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy","volume":"69","author":"Mattoo","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.coi.2025.102564_bib13","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/art.40469","article-title":"CD8 alpha-subset of CD4+SLAMF7+ cytotoxic T cells is expanded in patients with IgG4-related disease and decreases following glucocorticoid treatment","volume":"70","author":"Della-Torre","year":"2018","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.coi.2025.102564_bib14","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-020-00361-0","article-title":"Association of circulating SLAMF7(+)Tfh1 cells with IgG4 levels in patients with IgG4-related disease","volume":"21","author":"Higashioka","year":"2020","journal-title":"BMC Immunol"},{"key":"10.1016\/j.coi.2025.102564_bib15","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.coi.2025.102564_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pan.2016.12.003","article-title":"International consensus for the treatment of autoimmune pancreatitis","volume":"17","author":"Okazaki","year":"2017","journal-title":"Pancreatology"},{"key":"10.1016\/j.coi.2025.102564_sbref17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00535-022-01857-9","article-title":"Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020","volume":"57","author":"Okazaki","year":"2022","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102564_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28405-x","article-title":"Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study","volume":"8","author":"Shirakashi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2025.102564_bib19","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gut.2008.172908","article-title":"Standard steroid treatment for autoimmune pancreatitis","volume":"58","author":"Kamisawa","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102564_bib20","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/gutjnl-2012-303617","article-title":"Long-term outcomes of autoimmune pancreatitis: a multicenter, international analysis","volume":"62","author":"Hart","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102564_bib21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2016-312049","article-title":"Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis","volume":"66","author":"Masamune","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102564_sbref22","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102564_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV reactivation","volume":"33","author":"Shouval","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.coi.2025.102564_bib24","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.27435","article-title":"Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease","volume":"62","author":"Khosroshahi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102564_bib25","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/gutjnl-2012-302886","article-title":"Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience","volume":"62","author":"Hart","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102564_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40266-018-0534-6","article-title":"IgG4-related disease: beyond glucocorticoids","volume":"35","author":"Akiyama","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.coi.2025.102564_bib27","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/rheumatology\/kez380","article-title":"Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis","volume":"59","author":"Omar","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102564_bib28","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.pan.2021.06.009","article-title":"Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: a systematic review and meta-analysis","volume":"21","author":"Lanzillotta","year":"2021","journal-title":"Pancreatology"},{"key":"10.1016\/j.coi.2025.102564_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.006","article-title":"Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis","volume":"127","author":"Liu","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.coi.2025.102564_bib30","article-title":"Efficacy of rituximab in autoimmune-mediated IgG4 pancreaticobiliary disease: a systematic review and meta-analysis","author":"Loganathan","year":"2024","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.coi.2025.102564_sbref31","article-title":"Efficacy and safety of glucocorticoid monotherapy versus the combination of glucocorticoid and immunosuppressive agents for immunoglobulin G4-related disease: a systematic review and meta-analysis","volume":"15","author":"Alsalamah","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.coi.2025.102564_bib32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00535-021-01817-9","article-title":"The clinical efficacy of azathioprine as maintenance treatment for autoimmune pancreatitis: a systematic review and meta-analysis","volume":"56","author":"Masaki","year":"2021","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.coi.2025.102564_bib33","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ng.3060","article-title":"A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia","volume":"46","author":"Yang","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.coi.2025.102564_bib34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/gutjnl-2012-303635","article-title":"Autoimmune pancreatitis in MRL\/Mp mice is a T cell-mediated disease responsive to cyclosporine A and rapamycin treatment","volume":"63","author":"Schwaiger","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.coi.2025.102564_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661196","article-title":"The role of B cells and B cell therapies in immune-mediated liver diseases","volume":"12","author":"Cargill","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102564_sbref36","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","article-title":"Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single arm, single centre, phase 2 pilot trial","volume":"5","author":"Perugino","year":"2023","journal-title":"Lancet Rheuma"},{"key":"10.1016\/j.coi.2025.102564_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210400","article-title":"Could abatacept directly target expanded plasmablasts in IgG4-related disease?","volume":"75","author":"Carvajal Alegria","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102564_bib38","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/annrheumdis-2016-209368","article-title":"Efficacy of abatacept for IgG4-related disease over 8 months","volume":"75","author":"Yamamoto","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102564_sbref39","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2665-9913(21)00359-3","article-title":"Abatacept in IgG4 related disease: a prospective, open-label, single-arm, single centre, proof-of-concept study","volume":"4","author":"Matza","year":"2022","journal-title":"Lancet Rheuma"},{"key":"10.1016\/j.coi.2025.102564_bib40","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1080\/02770903.2021.2022158","article-title":"Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report","volume":"59","author":"Otani","year":"2022","journal-title":"J Asthma"},{"key":"10.1016\/j.coi.2025.102564_sbref41","article-title":"IgG4-related disease administered dupilumab: case series and review of the literature","volume":"9","author":"Kanda","year":"2023","journal-title":"RMDOpen"},{"key":"10.1016\/j.coi.2025.102564_bib42","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2019-216368","article-title":"Dupilumab as a novel steroid sparing treatment for IgG4-related disease","volume":"79","author":"Simpson","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:07:06Z","timestamp":1779084426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":42,"alternative-id":["S0952791525000408"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102564","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u2018Can we cure IgG4-related diseases?\u2019","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102564"}}